Equity Overview
Price & Market Data
Price: $1.37
Daily Change: -$0.01 / 0.73%
Daily Range: $1.36 - $1.45
Market Cap: $15,906,696
Daily Volume: 25,464
Performance Metrics
1 Week: -5.19%
1 Month: 17.74%
3 Months: 30.36%
6 Months: 10.61%
1 Year: -9.32%
YTD: 4.29%
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country:
Details
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.